Dopamine versus norepinephrine for low blood pressure in newborns with pulmonary hypertension
Official title: Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial
Run by University of California, Davis · NCT07322133 · Data updated 2026-11-12
This pilot test compares norepinephrine and dopamine as the first medicine to raise blood pressure in term and late‑preterm newborns with pulmonary hypertension and hypoxemic respiratory failure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | Any age to 28 Days |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Status | Recruiting |
| Started | October 30, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | August 18, 2026 |
| Trial ID | NCT07322133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Term and late‑preterm infants (postmenstrual age >34 6/7 weeks and postnatal age ≤28 days) on respiratory support with echocardiographic pulmonary hypertension and systemic hypotension despite a 10–20 mL/kg fluid bolus are the intended participants.
✕Probably not a fit
Extremely preterm infants (<32 weeks), those with severe refractory hypoxic respiratory failure (OI >35 or SpO2 <75% on 100% FiO2), lethal anomalies, or complex congenital heart disease are excluded and would not be expected to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, cluster-randomized pilot trial at UC Davis enrolling term and late‑preterm neonates with echocardiographic pulmonary hypertension, hypoxemic respiratory failure, and systemic hypotension that persists after a fluid bolus. Eligible infants on respiratory support and meeting blood pressure and oxygenation criteria are randomized to receive either dopamine or norepinephrine as first-line vasoactive therapy. The study measures short-term hemodynamic and oxygenation responses after initiation of the assigned vasopressor. The goal is to compare effects on systemic blood pressure and pulmonary vascular tone to inform choice of initial vasopressor in PPHN.
Why it matters
Potential benefit: If successful, the trial could identify a vasopressor strategy that raises systemic pressure without worsening pulmonary vascular resistance, improving oxygenation and clinical stability for affected newborns.
How similar studies have gone: There are animal and observational data suggesting dopamine may raise pulmonary vascular resistance and norepinephrine may spare the pulmonary circulation, but there are no prior prospective randomized trials directly comparing these drugs in neonates with PPHN.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Postmenstrual age \> 34 6/7 weeks and Postnatal age ≤ 28 days 2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3 3. Echocardiographic evidence of pulmonary hypertension 4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL/kg fluid bolus Permissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO/ASD, VSD \< 2 mm Exclusion Criteria: 1. Gestational age \< 32 weeks 2. Severe hypoxic respiratory failure (OI \> 35 or SpO2 \< 75% on 100% FiO2 for \> 60 minutes) 3. Lethal anomalies (e.g., trisomy 13 or 18) 4. Complex congenital heart disease beyond specified criteria
Where it's running
-
UC Davis Children's Hospital
Sacramento, California, United States Recruiting
Study contacts
- Principal investigator: Deepika Sankaran, MD — UC Davis Health
- Study coordinator: Solomon P Tatagiri, MBBS
- Email: solomontp@gmail.com
- Phone: 916-734-8672
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pleth Variability Index to predict low blood pressure during maintenance hemodialysis
This will test whether a simple pulse-oximeter reading (PVI) can help predict which adults on routine hemodialysis will develop low blood pressure so clinicians can act earlier.
-
Optimising high-flow oxygen settings in hypoxemic distress using depth-camera lung-volume measurements
This trial tests whether adjusting high-flow oxygen delivery based on lung volumes measured by a depth camera can reduce the need for intubation in ICU patients with hypoxemic respiratory failure.
-
Early treatment with noradrenaline for shock in emergency departments
This study tests if giving noradrenaline right away helps people in shock feel better and recover faster than just using standard fluids.
-
Comparing helmet ventilation, CPAP, and high-flow oxygen for respiratory failure
This study is testing whether helmet ventilation, CPAP, or high-flow oxygen can help people with serious breathing problems avoid needing a breathing tube.
-
Predicting HFNC Failure in Acute Hypoxemic Respiratory Failure using Metabolomics and Clinical Data
This study tests whether metabolomic blood profiles combined with routine clinical data can predict which adults with acute hypoxemic respiratory failure on high-flow nasal cannula will fail and need escalation of care.
-
Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure
This study tests whether allowing spontaneous breathing or using controlled ventilation is better for adults with acute hypoxemic respiratory failure who need invasive mechanical ventilation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.